SOX6 suppresses the development of lung adenocarcinoma by regulating expression of p53, p21CIPI, cyclin D1 and β-catenin

Liyan Lv1, Min Zhou2, Jian Zhang3, Fang Liu4, Li Qi5, Shuai Zhang4, Yi Bi6 and Yan Yu4

1 Department of Oncology, The First Affiliated Hospital of Harbin Medical University, China
2 Department of Pathology, The First Affiliated Hospital of Harbin Medical University, China
3 Department of Thoracic Surgery, The First Affiliated Hospital of Harbin Medical University, China
4 The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, China
5 Department of Radiation Oncology, The Second Affiliated Hospital of Harbin Medical University, China
6 Hemodialysis Department, Heilongjiang Provincial Electric Power Hospital, Harbin, China

Keywords
β-catenin; cyclin D1; lung adenocarcinoma; p21CIPI; p53; SOX6

Correspondence
Y. Yu, The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital, No. 150 Haping Road, Harbin 150081, China
Fax: +86 451 8629 8727
Tel: +86 451 8629 8727
E-mail: yuyan@ems.hrbmu.edu.cn

(Last updated 13 November 2019)

doi:10.1002/2211-5463.12762

Lung cancer is the main cause of cancer death worldwide, and its incidence is the second highest among all cancers [1]. Non-small-cell lung cancer (NSCLC) represents approximately 80% of lung cancers. At present, the pathogenesis of lung cancer is not completely clear, and the prognosis of lung cancer is still poor because of its high degree of malignancy, rapid progression and the frequent detection of distant metastasis at initial diagnosis [2,3]. Therefore, further exploration and discovery of new target genes of therapeutic value is of great significance for improving the diagnosis and prognosis of lung cancer. The Y-related transcription factor family (SOX) includes 30 members, and Sry-related high-mobility group box6 (SOX6) belongs to the D group with SOX5 and SOX13 [4,5]. SOX6 is specifically expressed during the development of the central nervous system and the formation of early embryonic cartilage and muscle tissue, and plays an important role in cell growth, development and proliferation [6,7]. Recent studies have also indicated that the SOX6 acts as an oncogene or tumor suppressor in various cancers, and expression of SOX6 is closely related to the occurrence, development and prognosis of human

Abbreviations
MTT, 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide; NSCLC, non-small-cell lung cancer; SOX6, Sry-related high-mobility group box6.
Role of SOX6 in lung adenocarcinoma

L. Lv et al.

Many studies have investigated the role of SOX5 in lung cancer. A recent study showed that SOX5 is required for the development of the lung, and that SOX5 can drive the malignant phenotype of NSCLC cells [16]. SOX5 can promote the metastasis of lung adenocarcinoma through the epithelial–mesenchymal transition and is an adverse prognostic factor of lung adenocarcinoma [17]. The amino acid sequences of the high-mobility group boxes of SOX5 and SOX6 are highly similar, suggesting that SOX5 and SOX6 might perform similar functions in certain cells [18]. In contrast with the research in SOX5, studies on the role of SOX6 in lung cancer are relatively rare. One study identified SOX6 as a target of miR-1269a in NSCLC, and miR-1269a promotes NSCLC growth by down-regulating the expression of SOX6 [19]. The precise role of SOX6 in lung cancer and its related molecular mechanisms remain to be identified. Here, we investigated the expression of SOX6 in lung adenocarcinoma and its role and potential mechanism of action in tumor development.

Materials and methods

The experimental protocol was approved by the Institute of Laboratory of Hematology and Cancer Center of The First Affiliated Hospital of Harbin Medical University. All methods were performed in accordance with the approved guidelines, and written informed consent was obtained from all patients. All procedures performed in studies involving human participants were in accordance with the ethical standards of the institution, the National Research Committee, or both, and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.

Patients and tissue specimens

Thirty pairs of lung adenocarcinoma tissues and adjacent nontumor tissues were acquired from the Department of Thoracic Surgery of The First Affiliated Hospital of Harbin Medical University and the Department of Thoracic Surgery of Heilongjiang Cancer Hospital. Thirty pairs of fresh tissue were removed surgically and frozen in liquid nitrogen immediately after surgery. The tissue samples were stored in a refrigerator at –80 °C. Paraffin-embedded tissues (n = 145) were obtained from patients who underwent surgery for lung adenocarcinoma at the Department of Thoracic Surgery of The First Affiliated Hospital of Harbin Medical University from January 2009 to January 2012. The patients did not receive treatment before surgery. Patients granted their informed consent to participate in the study. Clinical data of patients included in this study are detailed in Tables S1 and S2.

Immunohistochemistry

Immunohistochemistry was performed according to published protocols. Tissue sections were deparaffinized, blocked with 10% serum for 10 min and then incubated with SOX6 Ig (1 : 500, ab30455; Abcam, Cambridge, UK) at 37 °C for 30 min and then overnight at 4 °C. Sections were then incubated with secondary Ig (PV9000; ZSGB-BIO Inc., Beijing, China). The levels of SOX6 in the nuclei of normal lung and lung adenocarcinoma cells were evaluated semiquantitatively according to the previously published protocols. Sections were evaluated and scored for the degree of SOX6-positive staining as follows: 0, no staining; 1, light staining (light yellow); 2, moderate staining (yellow); or 3, strong staining (yellow-brown). Sections were evaluated for the percentage of stained cells as follows: 0, <5%; 1, 5%–25%; 2, 25%–50%; or 3, >50%. The staining degree score was multiplied by the score for the percentage of stained cells. Sections with overall scores of 0–3 were negative, and sections with overall scores ≥4 were positive. The stained tissue sections were evaluated using light microscopy (original magnification ×200 or ×400). According to the pathological diagnostic criteria, the degrees of differentiation of lung adenocarcinoma are defined as follows: well differentiated (>95% gland duct formation), moderately differentiated (50–95% gland duct formation) and poorly differentiated (0–49% gland duct formation). Two pathologists who were uninformed of the patients’ clinical data assessed the data for the nuclear expression of SOX6.

Real-time quantitative RT-PCR assay scores

Total RNA was extracted using TRizol reagent (TIANGEN Biochemical Technology Co., Ltd, Beijing, China) according to the manufacturer’s instructions. The concentration and purity of the RNA preparations were determined using a NanoDrop ND-2000 spectrophotometer (Thermo Scientific, Shanghai, China) and denaturing agarose gel electrophoresis. The PrimeScript cDNA RT
Reagent Kit with gDNA (Eraser RR047B; Takara Bio Inc., Dalian, China) was used for reverse transcription, and the reactions were performed according to a published protocol. The PCR primer sequences (Invitrogen, Carlsbad, CA, USA) were as follows: SOX6 sense and antisense primers (GenBank: AF309034.1), (forward) 5'-GGGAAAGTCAATGAAGATGGAA-3' and (sox6 reverse) 5'-CGCTTTAATGTGGCTCGCT-3'; 18S ribosomal RNA sense and antisense primers (GenBank: MG595728.1) (forward) 5'-GTAACCCGTGAACCCATT-3' and (reverse) 5'-CCATCAATCGGTAGTAGCG-3'.

Western blotting
Radioimmunoprecipitation assay (R0278; Sigma-Aldrich, St Louis, MO, USA) protein extraction reagent was used to extract total cellular and tissue proteins, and the bicinchoninic acid method was used to quantitate the amount of protein. Detection of immune complexes was performed according to a published protocol [20]. Antibodies were diluted as follows: anti-SOX6 (ab30455; Abcam), anti-p53 (1C12; 2524; 1 : 500; Cell Signaling Technology, Danvers, MA, USA); anti-p21CIP1 (60214-1-1g, 1 : 1000; Proteintech Group Inc., Wuhan, Hubei, China), anti-catenin (66379-1-C12; 2524; 1 : 500; Cell Signaling Technology, Danvers, MA, USA); anti-p53 (1C12; 2524; 1 : 500; Cell Signaling Technology, Danvers, MA, USA); anti-p21CIP1 (60214-1-1g, 1 : 1000; Proteintech Group Inc., Wuhan, Hubei, China), anti-catenin (66379-1-1g, 1 : 1000; Proteintech Group Inc.) and anti-cyclin D1 (60186-1-1g, 1 : 1000; Proteintech Group Inc.).

Cell culture and transfection
The lung cancer cell lines A549 and HCC827 were obtained from the Laboratory of Hematology and Tumor Center of The First Affiliated Hospital of Harbin Medical University and approved by the Laboratory of Hematology and Tumor Center of this hospital. All methods were performed in accordance with the approved guidelines. A549 and HCC827 cells were cultured at 37 °C in 90% RPMI 1640 culture medium (Invitrogen) containing 10% FBS and 1% penicillin-streptomycin in an atmosphere containing 5% CO₂.

To establish stable cell lines, we transfected cells with the PCMV6-Entry SOX6 expression vector (RC227487; OriGene Technologies Inc., Rockville, MD, USA) using Lipofectamine 2000 Transfection Reagent (Invitrogen) according to the manufacturer’s instructions. Cells (1.5 × 10⁵ cells-mL⁻¹) were plated the day before transfection and then cultured for at least 12 h before transfection. Clones that stably expressed SOX6 (SOX6-A549 or SOX6-HCC827) were pooled, and the SOX6 cDNA prepared from each pool was resequenced. A549 and HCC827 cells transfected with the empty vector (Vec-A549 and Vec-HCC827) were used as controls.

Flow cytometry
Cells were resuspended in serum-free medium and adjusted to 1 × 10⁴ cells-mL⁻¹; the cells were centrifuged and washed. The cell density was then adjusted to 1 × 10⁶ mL⁻¹ with 10 mM PBS, and 100 μL of the cell suspension was aliquoted into a separate tube. Next, 400 μL of cell cycle detection reagent (558662; BD Biosciences-CN, Shanghai, China) was added, and the reaction was incubated at room temperature for 30 min. The cells were centrifuged, resuspended in 500 μL of 10 mM PBS, and analyzed using flow cytometry (BD FACSCanto II, Franklin Lake, NJ, USA). The cell cycle was analyzed using FLOWJO software (Leonard Herzenberg laboratory of Stanford University, Stanford, CA, USA).

Cell proliferation assay
Cell proliferation was determined using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) method. Cells were added to a 96-well cell culture plate (100 μL per well). The MTT assay was performed after 48 h, and the transfection medium was replaced according to the manufacturer’s instructions. Attenuances were measured at D₅₇₀ nm.

Colony formation assay
Cells transfected for 24 h were trypsinized, and the cell density was adjusted to 1 × 10⁶ cells mL⁻¹. The suspension was added to six-well cell culture plates (20 μL per well), and colonies were counted after 14 days (>50 cells per colony).

Wound healing assay
Before the transfected cells changed their fluids, we used a yellow micropipette tip to introduce a ‘wound gap’ into the cell layer in the wells of a six-well cell culture plate. The cells were washed and growth medium was added. The cells were photographed (original magnification ×100) at 0, 24 and 48 h.

Transwell migration assays
Transwell polycarbonate membrane cell culture plate inserts (8 µm; CLS3422; Sigma-Aldrich) were used for the cell migration assay. Twenty-four hours after transfection, the cell density was adjusted to 5 × 10⁵ mL⁻¹. Culture medium (500 μL) was added to the lower chamber of the Transwell insert, and 50 μL of Matrigel was added to the upper chamber. After 24 h, the cells were fixed with paraformaldehyde and stained with crystal violet. Photographs were taken of the migrated cells, and the numbers of cells in 200 fields were counted.

Statistical analysis
Statistical analysis was performed using spss 19.0 software (SPSS Inc., Chicago, IL, USA). The relationships between
the expression of SOX6 and patient clinicopathological features were evaluated using the chi-square test. The Student’s t-test was performed to evaluate significant differences between control and experimental groups. The Kaplan–Meier method was used to analyze survival, and the data were compared with those acquired using log analysis. The relationships between SOX6 expression and clinicopathological parameters, and the prognosis of patients with lung adenocarcinoma were assessed using univariate and multivariate analyses [21–23]. A P-value <0.05 indicated a significant difference.

Results

We used RT-PCR to detect the expression of SOX6 mRNA in lung cancer samples. We examined SOX6 mRNA in 30 pairs of adjacent nontumor tissues and lung adenocarcinomas, and detected significantly higher levels in the nontumor tissues (22/30, 73%); the difference in SOX6 mRNA levels was statistically significant (P < 0.001; Fig. 1A). Immunohistochemical analysis of paraffin-embedded sections from 145 pairs of lung adenocarcinomas and adjacent nontumor tissues revealed that SOX6 was frequently expressed in nontumor tissues (sections with overall scores ≥ 4, 132/145, 91.3%). In contrast, the levels of SOX6 were lower in lung adenocarcinomas (sections with overall scores ≥ 4, 57/145, 39%). The difference in SOX levels was statistically significant (P < 0.05). Western blot results further confirmed that the expression of SOX6 protein was down-regulated in lung adenocarcinoma tissues compared with adjacent nontumor tissues (Fig. 1B,C).

Low SOX6 expression is associated with poor prognosis of patients with lung adenocarcinoma

To assess the relationship between the expression of SOX6 and the clinicopathological features and prognosis of patients with lung adenocarcinoma, we compared SOX6 expression in the 145 lung adenocarcinomas with clinicopathological characteristics. We found that low SOX6 expression significantly
correlated with poor differentiation ($P < 0.001$) and lymph node metastasis ($P < 0.05$; Table 1). Univariate analysis revealed that low SOX6 expression ($P < 0.001$), poor differentiation ($P < 0.001$), lymph node metastasis ($P < 0.001$) and late disease stage ($P < 0.001$) were significant prognostic factors (Table 2). Multivariate analysis showed that low SOX6 expression ($P < 0.001$), poor differentiation ($P < 0.001$), lymph node metastasis ($P < 0.001$) and late disease stage ($P < 0.001$) were independent prognostic factors (Table 3). These results suggest that patients with low Sox6 expression are often accompanied by poor differentiation and lymph node metastasis, and their prognosis is poor.

The log rank test showed that disease-related survival (date of diagnosis to the date of cancer-related death or last follow-up) of lung adenocarcinoma patients with low SOX6 expression was significantly shorter compared with that of patients with normal levels of SOX6 (median survival, 22.6 versus 36.3 months, respectively; $P < 0.001$; Fig. 2).

**SOX6 inhibits the development and metastasis of lung adenocarcinoma**

We next evaluated the effect of SOX6 on tumor formation and cell proliferation in cell proliferation and colony formation assays using cell lines stably expressing SOX6 (SOX6-A549 and SOX6-HCC827). Both SOX6-A549 and SOX6-HCC827 cells showed significantly reduced colony formation activity compared with control cells transfected with the empty vector (Vec-A549 and Vec-HCC827; SOX6-A549 cells, $P < 0.05$; SOX6-HCC827 cells, $P < 0.01$; Fig. 3A,B). MTT assays revealed that proliferation of SOX6-A549 significantly reduced colony formation activity compared with control cells transfected with the empty vector (Vec-A549 and Vec-HCC827; SOX6-A549 cells, $P < 0.05$; SOX6-HCC827 cells, $P < 0.01$; Fig. 3A,B).

### Table 1. Analysis of the relationship between clinicopathological characteristics and SOX6 expression. SOX6 expression was detected by immunohistochemistry.

| Clinicopathological features | Cases, n | SOX6 expression, n (%) | $\chi^2$ | $P$-value |
|-----------------------------|----------|------------------------|---------|-----------|
| Tumor cell differentiation  |          |                        |         |           |
| Well                        | 52       | 19 (36.6)              | 33 (63.4)| 21.5606   | 0.000*   |
| Moderate                    | 50       | 34 (68.0)              | 16 (32.0)|           |          |
| Poor                        | 43       | 35 (81.3)              | 8 (18.7) |           |          |
| Sex                         |          |                        |         |           |
| Male                        | 71       | 44 (62.0)              | 27 (38.0)| 0.2685    | 0.606    |
| Female                      | 74       | 44 (60.0)              | 30 (40.0)|           |          |
| Age, years                  |          |                        |         |           |
| ≤60                         | 77       | 46 (59.7)              | 31 (40.3)| 0.062     | 0.803    |
| >60                         | 68       | 42 (61.8)              | 26 (38.2)|           |          |
| Lymph node metastasis       |          |                        |         |           |
| N0                          | 93       | 50 (53.7)              | 43 (46.3)| 5.2146    | 0.022*   |
| N1                          | 52       | 38 (73.1)              | 14 (26.9)|           |          |
| TNM stage                   |          |                        |         |           |
| I                           | 88       | 48 (54.5)              | 40 (45.5)| 4.2988    | 0.117    |
| II                          | 35       | 23 (65.7)              | 12 (34.3)|           |          |
| III                         | 22       | 17 (77.3)              | 5 (22.7) |           |          |

*aDown-regulation: sections with overall scores of 0–3; bNormal: sections with overall scores ≥4; *$P < 0.05$.**

### Table 2. Univariate analysis of factors related to disease-specific survival.

| Variables                  | Hazard ratio | 95% CI       | $P$-value |
|----------------------------|--------------|--------------|-----------|
| SOX6                       | 0.377        | 0.258–0.551  | 0.000*    |
| Sex                        | 1.077        | 0.761–1.523  | 0.676     |
| Age                        | 1.009        | 0.986–1.032  | 0.464     |
| Differentiation            | 1.848        | 1.467–2.327  | 0.000*    |
| Lymph nodes metastasis     | 2.205        | 1.532–3.179  | 0.000*    |
| Stage                      | 1.898        | 1.493–2.412  | 0.000*    |

*$P < 0.05$.

### Table 3. Multivariate analysis of factors related to disease-specific survival.

| Variables                  | Hazard ratio | 95% CI       | $P$-value |
|----------------------------|--------------|--------------|-----------|
| SOX6                       | 0.463        | 0.310–0.702  | 0.000*    |
| Sex                        | 1.319        | 0.915–1.901  | 0.138     |
| Age                        | 1.026        | 1.003–1.054  | 0.029*    |
| Differentiation            | 1.493        | 1.139–1.956  | 0.004*    |
| Lymph nodes metastasis     | 1.487        | 0.907–2.437  | 0.116     |
| Stage                      | 2.836        | 1.580–5.090  | 0.000*    |

*$P < 0.05$.**
and SOX6-HCC827 cells was significantly inhibited compared with the respective empty vector-transfected controls ($P < 0.01$; Fig. 3C).

We further examined the effect of SOX6 expression on the invasiveness of lung adenocarcinoma cells using wound healing and Transwell assays. The migration of SOX6-A549 and SOX6-HCC827 cells was significantly reduced compared with the respective controls (Fig. 4A). Similarly, the invasiveness of the stable SOX6-expressing clones (SOX6-A549 and SOX6-HCC827) was reduced compared with the empty vector-transfected controls (SOX6-A549 cells, $P < 0.05$; SOX6-HCC827 cells, $P < 0.01$; Fig. 4B).

The mechanism of the inhibitory effect of SOX6 on the cell cycle of lung adenocarcinoma cells

To identify the mechanism through which SOX6 inhibits tumor growth, we next analyzed the cell cycle. Flow cytometry revealed that the numbers of SOX6-A549 and SOX6-HCC827 cells in the G0/G1 phase were significantly increased compared with controls, with a significant decrease in S phase cells, indicating that SOX6 inhibited the G1/S transition ($P < 0.05$; Fig. 5A, B). Overexpression of SOX6 in SOX6-transfected lung cancer cells (SOX6-A549 and SOX6-

**Fig. 2.** Kaplan–Meier analysis of the relationship between survival and SOX6 expression in patients with lung adenocarcinoma. SOX6 = 1 (staining score ≥ 4), patients with normal levels of SOX6 expression ($n = 57$; median survival, 36.3 months; brown curve); SOX6 = 0 (staining score = 0–3), patients with down-regulation of SOX6 expression ($n = 88$; median survival, 22.6 months; blue curve); log rank test, $P < 0.001$.

**Fig. 3.** SOX6 inhibits the proliferation of lung adenocarcinoma cells. (A) Example of inhibition of colony formation in a monolayer culture by SOX6. (B) Number of colonies versus controls. **$P < 0.05$, ***$P < 0.01$. (C) Growth curves of SOX6-HCC827 and Vec-HCC827 cells and SOX6-A549 and Vec-A549 cells (left). Histogram of the number of cells in cell cultures after 48 h (right). $n = 3$. Student’s $t$-test was used. Error bars represent SD. ***$P < 0.01$. 

140
HCC827) was confirmed by western blot analysis (Fig. 6A). We next performed western blotting to investigate the effects of SOX6 on the levels of cell cycle regulatory proteins (p53, p21\textsuperscript{CIP1}, cyclin D1 and β-catenin). The levels of p53 and p21\textsuperscript{CIP1} were significantly increased in SOX6 stable cells compared with controls, whereas the levels of cyclin D1 and β-catenin were significantly decreased (P < 0.001; Fig. 6B,C).

Discussion

The gene-encoding transcription factor SOX6, which was first isolated from mouse testes [24], is located in homologous chromosome region 11p15.3-15.2 and expressed in various tissues. Recent studies have demonstrated that SOX6 not only plays an important role in chondrocyte and skeletal muscle differentiation, but also regulates erythropoiesis, myocardial cell proliferation and insulin secretion [25]. It has been reported that children with SOX6 mutations experience development of global developmental delay, progressive relapsing–remitting parkinsonism and spinal syrinx [25]. Some studies have shown that the abnormal expression of Sox6 is related to the occurrence and development of cancer. For example, down-regulation of SOX6 expression in pancreatic cancer, esophageal cancer and ovarian cancer can inhibit the proliferation, migration and invasion of cancer cells, thus inhibiting the invasion and metastasis of cancer [14,15,26].

The abnormal expression of SOX6 is also associated with the prognosis of some tumors. SOX6 acts as a tumor suppressor in esophageal cancer and is an independent prognostic factor of esophageal cancer [9]. The expression level of SOX6 in hepatocellular carcinoma is negatively associated with tumor stage, and
patients with down-regulated expression of SOX6 show poor prognosis [8]. At present, whether the expression of SOX6 is related to the prognosis of lung cancer is not clear.

No studies have explored the role of SOX6 in lung cancer; thus, our current research provides some preliminary data in this area and suggests a new direction for further exploration of new targets in lung adenocarcinoma.

We showed that the expression of SOX6 in lung adenocarcinoma tissues was down-regulated at both the protein and the mRNA level. These results suggest that SOX6 may function as a tumor suppressor in lung adenocarcinoma, and the down-regulation of SOX6 expression may be related to the occurrence and development of lung adenocarcinoma.

To investigate the clinical significance of down-regulation of SOX6 expression in lung adenocarcinoma, we retrospectively analyzed the clinical data of 145 patients with lung adenocarcinoma. The results showed that the expression of SOX6 was closely related to the degree of differentiation and lymph node invasion.

**Fig. 5.** SOX6 inhibits the G1/S transition. (A) Flow cytometry was performed to assess the cell cycle. The percentage of cells in S phase was lower in SOX6-A549 and SOX6-HCC827 cells compared with those of the respective control cells. (B) Histogram of cell ratio at each phase in the stable SOX6-expressing clones (SOX6-A549 and SOX6-HCC827) compared with the untransfected controls (Vec-A549 and Vec-HCC827). \( n = 3 \). Student’s t-test was used. Error bars represent SD. **\( P < 0.05 \), ***\( P < 0.01 \).
metastasis. Patients with poorly differentiated or lymph node metastasis often also showed down-regulation of SOX6 expression. Univariate and multivariate analyses suggest that SOX6 expression was related to disease-related survival and might be an independent prognostic factor. Survival analysis showed that patients with down-regulated SOX6 expression had significantly shortened disease-related survival and poor prognosis compared with patients with normal expression of Sox6. These results suggest that SOX6 expression may serve as a potential prognostic marker.

In this study, we found that SOX6 was down-regulated in patients with lung adenocarcinoma, and in vitro cell experiments indicated that SOX6 inhibits the proliferation, migration and invasion of lung adenocarcinoma cells; thus, SOX6 may possibly function as a tumor suppressor. These results are consistent with those reported in the literature regarding the role of SOX6 in other tumors. For example, in prostate cancer, miRNA-671 promotes tumor proliferation by inhibiting the expression of SOX6 [14]. Furthermore, miRNA-96 and miRNA-155 decrease proliferation, migration and invasion of hepatocellular carcinoma cells by inhibiting the expression of SOX6 [13,27]. These studies support the inhibitory activity of SOX6 in tumors.

The oncogenesis of lung cancer involves the activities of numerous signaling pathways, particularly the Wnt/β-catenin signaling pathways [28,29]. We demonstrated that SOX6 reduced the expression of β-catenin in a lung adenocarcinoma cell line, suggesting that the tumor suppressor function of SOX6 may be associated with this signaling pathway. Wnt/β-catenin signaling pathways mediate diverse processes, including cell

![Fig. 6. Regulation of Sox6 on p53, p21CIP1, β-catenin and Cyclin D1. (A) Western blot was used to detect the overexpression of SOX6 in stably transfected A549 and HCC827 cell lines. Empty vector-transfected cells (Vec-A549/Vec-HCC827) were used as controls. (B) Western blot analysis of the expression of p53, p21CIP1, β-catenin and cyclin D1 in SOX6-A549 and SOX6-HCC827 cells. GAPDH served as a loading control. (C) Histogram of protein expression in the stable SOX6-expressing clones (SOX6-A549 and SOX6-HCC827) compared with the untransfected controls (Vec-A549 and Vec-HCC827). n = 3. Student’s t-test was used. Error bars represent SD. ***P < 0.001.](image-url)
proliferation, migration, differentiation and death [30]. The core feature of these mechanisms is the regulation of the stability of β-catenin. β-Catenin is a multifunctional protein that interacts with E-cadherin at cell junctions and participates in the formation of adhesions, whereas free β-catenin enters the nucleus to form a complex with lymphoid-enhancing factor/T cell factor [31,32]. This complex acts as a transcriptional regulator for many genes and activates downstream target genes myelocytomatosis oncogene and cyclin D1 to promote tumor cell differentiation and proliferation [33,34].

Cyclin D1 is G1/S-specific cyclin [35]. p21CIPI is a cyclin-dependent kinase inhibitor that negatively regulates the cell cycle and inhibits the growth of tumor cells [36]. The gene encoding p21CIPI is also the main downstream target gene of p53. p53 represses G1 cell cycle progression by up-regulating p21CIPI, and the G1/S transition is the key to the cell cycle [37]. Recent studies have shown that SOX6 up-regulates the expression of p21CIPI protein in a high-mobility group domain-dependent manner through the p14ARF-HDM2-p53 axis to play a role in tumor inhibition [38]. To clarify the mechanism of SOX6 in lung adenocarcinoma, we carried out cell cycle and immunoblotting assays. We found that lung adenocarcinoma cells stably transfected with SOX6 showed increased numbers of cells in G1 phase, indicating that SOX6 negatively regulates G1 phase transition in lung adenocarcinoma cells. These data suggest that SOX6 may function as a tumor suppressor by regulating the cell cycle in lung adenocarcinoma. We also found that p53 and p21CIPI levels were significantly increased in lung adenocarcinoma cells transfected with SOX6, whereas the expressions of β-catenin and cyclin D1 were significantly decreased. This result was consistent with the role of SOX6 in esophageal squamous cell carcinoma [9]. These findings suggest that the inhibitory effect of SOX6 in lung adenocarcinoma may be related to the inhibition of G1 transition through up-regulation of p53 and p21CIPI expression and down-regulation of β-catenin and cyclin D1 expression. Animal experiments will be required to confirm whether SOX6 acts as a tumor suppressor.

Conclusions

Our study suggests that SOX6 may be a tumor suppressor in lung adenocarcinoma, and our results show that the prognosis of patients with lung adenocarcinoma with low SOX6 expression is poor. These findings suggest that SOX6 may be a potential new therapeutic target and molecular predictor of lung adenocarcinoma.

Acknowledgements

The authors thank YH Gu (Department of Pathology, The First Affiliated Hospital of Harbin Medical University), YG Lang and QW Meng (Department of Thoracic Surgery and The Sixth Department of Medical Oncology, Harbin Medical University Cancer Hospital) for directing this project. This work was supported by the National Natural Scientific Foundation of China (grant 81773133) and the Natural Scientific Foundation of Heilongjiang Province (grant H2016051). The authors thank L. Bianji, Edanz Editing China (https://www.liwenbianji.cn/ac), for editing the English text of a draft of this manuscript.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

LL was responsible for literature review, experiment design, experiment execution, data collection and compilation, as well as manuscript writing. LL, MZ and JZ were responsible for specimen collection and experiment execution. FL and LQ were responsible for statistical analysis. LL and SZ were responsible for collecting clinical case data. LL and YB were responsible for literature review. YY was responsible for overall experimental design, feasibility analysis, experimental process supervision, and manuscript review and revision.

References

1 Siegel RL, Miller KD and Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67, 7–30.
2 Qi HW, Xin LY, Xu X, Ji XX and Fan LH (2014) Epithelial-to-mesenchymal transition markers to predict response of Berberine in suppressing lung cancer invasion and metastasis. J Transl Med 12, 22.
3 You J, Li Y, Fang N, Liu B, Zu L, Chang R, Li X and Zhou Q (2014) MiR-132 suppresses the migration and invasion of lung cancer cells via targeting the EMT regulator ZEB2. PloS ONE ONE 9, e91827.
4 Ling KH, Hewitt CA, Beissbarth T, Hyde L, Banerjee K, Cheah PS, Cannon PZ, Hahn CN, Thomas PQ, Smyth GK et al. (2009) Molecular networks involved in mouse cerebral corticogenesis and spatio-temporal regulation of Sox4 and Sox11 novel antisense
transcripts revealed by transcriptome profiling. *Genome Biol* **10**, R104.

5 Sinclair AH, Berta P, Palmer MS, Hawkins JR, Griffiths BL, Smith MJ, Foster JW, Frischauf A-M, Lovell-Badge R and Goodfellow PN (1990) A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. *Nature* **346**, 240–244.

6 Wang XY, Chen XL, Huang ZQ, Chen DW, Yu B, He J, Luo JQ, Luo YH, Chen H, Zheng P et al. (2017) MicroRNA-499-5p regulates porcine myofiber specification by controlling Sox6 expression. *Animal* **11**, 2268–2274.

7 Hagiwara N (2011) Sox6, jack of all trades: a versatile regulatory protein in vertebrate development. *Dev Dyn* **240**, 1311–1321.

8 Guo X, Yang M, Gu H, Zhao J and Zou L (2013) Decreased expression of SOX6 confers a poor prognosis in hepatocellular carcinoma. *Cancer Epidemiol* **37**, 732–736.

9 Qin YR, Tang H, Xie F, Liu H, Zhu Y, Ai J, Chen L, Li Y, Kwong DL, Fu L et al. (2011) Characterization of tumor-suppressive function of SOX6 in human esophageal squamous cell carcinoma. *Clin Cancer Res* **17**, 46–55.

10 Schlierf B, Friedrich RP, Roerig P, Felsberg J, Reifenberger G and Wegner M (2007) Expression of SoxE and SoxD genes in human gliomas. *Neuropath Appl Neurobiol* **33**, 621–630.

11 Ueda R, Yoshida K, Kawakami Y, Kawase T and Toda M (2004) Expression of a transcriptional factor, SOX6, in human gliomas. *Brain Tumor Pathol* **21**, 35–38.

12 Yu Y, Wang Z, Sun D, Zhou H, Wei X, Hou W, Ding Y, Ma Y and Hou Y (2018) miR-671 promotes prostate cancer cell proliferation by targeting tumor suppressor Sox6. *Eur J Pharmacol* **823**, 65–71.

13 Li Z and Wang Y (2018) miR-96 targets Sox6 and promotes proliferation, migration, and invasion of hepatocellular carcinoma. *Biochem Cell Biol* **96**, 365–371.

14 Jiang W, Yuan Q, Jiang Y, Huang L, Chen C, Hu G, Wan R, Wang X and Yang L (2018) Identification of Sox6 as a regulator of pancreatic cancer development. *J Cell Mol Med* **22**, 1864–1872.

15 Li H, Zheng D, Zhang B, Liu L, Ou J, Chen W, Xiong S, Gu Y and Yang J (2014) Mir-208 promotes cell proliferation by repressing Sox6 expression in human esophageal squamous cell carcinoma. *J Transl Med* **12**, 196.

16 Zou H, Wang S, Wang S, Wu H, Yu J, Chen Q, Cui W, Yuan Y, Wen X, He J et al. (2018) SOX5 interacts with YAP1 to drive malignant potential of non-small cell lung cancer cells. *Am J Cancer Res* **8**, 866–878.

17 Chen X, Fu Y, Xu H, Teng P, Xie Q, Zhang Y, Yan C, Xu Y, Li C, Zhou J et al. (2018) SOX5 predicts poor prognosis in lung adenocarcinoma and promotes tumor metastasis through epithelial-mesenchymal transition. *Oncotarget* **9**, 10891–10904.

18 Du B, Liu X, Zhang P, Zhang J, Ji K, Hu S, Yang S, Liu B and Fan R (2018) The role of sex-determining region Y-box 6 in melanogenesis in alpaca melanocytes. *J Dermatol Sci* **91**, 268–275.

19 Jin RH, Yu DJ and Zhong M (2018) MiR-1269a acts as an onco-miRNA in non-small cell lung cancer via down-regulating SOX6. *Eur Rev Med Pharmacol Sci* **22**, 4888–4897.

20 Xu MZ, Yao TJ, Lee NP, Ng IO, Chan YT, Zender L, Lowe SW, Poon RT and Luk JM (2009) Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. *Cancer* **115**, 4576–4585.

21 Wong KC (2011) Chi squared test versus Fisher’s exact test. *Hong Kong Med J* **17**, 427.

22 Stel VS, Dekker FW, Tripepi G, Zoccali C and Jager KJ (2011) Survival analysis I: the Kaplan-Meier method. *Nephron Clin Pract* **119**, c83–c88.

23 Zhang D and Quan H (2009) Power and sample size calculation for log-rank test with a time lag in treatment effect. *Stat Med* **28**, 864–879.

24 Connor F, Wright E, Denny P, Koopman P and Ashworth A (1995) The Sry-related HMG box-containing gene Sox6 is expressed in the adult testis and developing nervous system of the mouse. *Nucleic Acids Res* **23**, 3365–3372.

25 Scott O, Pugh J, Kiddoo D, Sonnenberg LK, Bamforth S and Goez HR (2014) Global developmental delay, progressive relapsing-remitting parkinsonism, and spinal syringa in a child with SOX6 mutation. *J Child Neurol* **29**, NP164–NP164.

26 Li Y, Xiao M and Guo F (2017) The role of Sox6 and Netrin-1 in ovarian cancer cell growth, invasiveness, and angiogenesis. *Tumour Biol* **39**, 1–9. https://doi.org/10.1177/1010428317705508

27 Xie Q, Chen X, Lu F, Zhang T, Hao M, Wang Y, Zhao J, McCrae MA and Zhuang H (2012) Aberrant expression of microRNA 155 may accelerate cell proliferation by targeting sex-determining region Y box 6 in hepatocellular carcinoma. *Cancer* **118**, 2431–2442.

28 Shapiro M, Akiri G, Chin C, Wisnivesky JP, Beasley MB, Weiser TS, Swanson SJ and Aaronson SA (2013) Wnt pathway activation predicts increased risk of tumor recurrence in patients with stage I nonsmall cell lung cancer. *Ann Surg* **257**, 548–554.

29 Chen B, Ma X, Liu S, Zhao W and Wu J (2012) Inhibition of lung cancer cells growth, motility and induction of apoptosis by Klotho, a novel secreted Wnt antagonist, in a dose-dependent manner. *Cancer Biol Ther* **13**, 1221–1228.

30 Tuluc S, Nayak NR, Kao LC, van Waes M, Huang J, Lobo S, Germeyer A, Lessey BA, Taylor RN, Suchanek E et al. (2003) Identification, characterization, and regulation of the canonical Wnt signaling pathway.
in human endometrium. J Clin Endocrinol Metab 88, 3860–3866.

31 Takahashi-Yanaga F and Kahn M (2010) Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res 16, 3153–3162.

32 Stewart DJ (2014) Wnt signaling pathway in non-small cell lung cancer. J Natl Cancer Inst 106, djt356.

33 Shi L, Wu YX, Yu JH, Chen X, Luo XJ and Yin YR (2017) Research of the relationship between beta-catenin and c-myc-mediated Wnt pathway and laterally spreading tumors occurrence. Eur Rev Med Pharmacol Sci 21, 252–257.

34 Han A, Song Z, Tong C, Hu D, Bi X, Augenlicht LH and Yang W (2008) Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol 583, 26–31.

35 Aaltomaa S, Eskelinen M and Lipponen P (1998) Expression of cyclin A and D proteins in prostate cancer and their relation to clinopathological variables and patient survival. Prostate 38, 175–182.

36 Parry D, Mahony D, Wills K and Lees E (1999) Cyclin D-CDK subunit arrangement is dependent on the availability of competing INK4 and p21 class inhibitors. Mol Cell Biol 19, 1775–1783.

37 Waldman T, Kinzler KW and Vogelstein B (1995) p21 is necessary for the p53-mediated G1 arrest in human cancer cells. Cancer Res 55, 5187–5190.

38 Wang J, Ding S, Duan Z, Xie Q, Zhang T, Zhang X, Wang Y, Chen X, Zhuang H and Lu F (2016) Role of p14ARF-HDM2-p53 axis in SOX6-mediated tumor suppression. Oncogene 35, 1692–1702.

Supporting information

Additional supporting information may be found online in the Supporting Information section at the end of the article.

Table S1. Clinical features of 30 patients with primary lung adenocarcinoma.

Table S2. Clinicopathological features and SOX6 expression in 145 informative patients with lung adenocarcinoma.